During the follow-up period, cumulative incidences of DKD progression, MACE, and all-cause mortality were 48.3%, 23.1%, and 38.9%, respectively, in the whole group; for incidences in CVD-b+/− or DKD-b+/− subgroups separately, see Table 3. This evidence concerns the gene PPIB and diabetic kidney disease.